Adjuvant systemic therapy for primary breast cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Surgical Clinics of North America

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0039-6109(05)70062-1PMID 10572552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

  2005cited by this paper
• Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

  1998cited by this paper
• Production of A Single Chain Anti-CEA Antibody From the Hybridoma Cell Line T84.66 Using a Modified Colony-Lift Selection Procedure to Detect Antigen-Positive ScFv Bacterial Clones

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group.

  1998cited by this paper
• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

  1998cited by this paper
• P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy

  1998cited by this paper
• Cancer incidence and mortality, 1973-1995: a report card for the U.S.

  1998cited by this paper
• Cancer incidence and mortality, 1973‐1995

  1998cited by this paper
• erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.

  1998cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

  1997cited by this paper
• NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel.

  1997cited by this paper
• High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

  1997cited by this paper
• Preoperative chemotherapy induces apoptosis in early breast cancer.

  1997cited by this paper
• Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.

  1997cited by this paper
• Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

  1997cited by this paper
• Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.

  1997cited by this paper
• HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

  1997cited by this paper
• Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.

  1997cited by this paper
• Combination chemotherapy studies with gemcitabine.

  1997cited by this paper
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

  1997cited by this paper
• bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.

  1997cited by this paper
• Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.

  1996cited by this paper
• Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.

  1996cited by this paper
• Ovarian ablation in early breast cancer: Overview of the randomised trials

  1996cited by this paper
• Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.

  1996cited by this paper
• Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy

  1995cited by this paper
• Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.

  1995cited by this paper
• 102. Adjuvant tamoxifen duration in a randomized trial

  1995cited by this paper
• Prognostic value of bcl-2 expression in invasive breast cancer.

  1995cited by this paper
• The natural history of breast cancer with more than 10 positive nodes.

  1995cited by this paper
• Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

  1995cited by this paper
• Meeting highlights: international consensus panel on the treatment of primary breast cancer.

  1995cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

  1995cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

  1995cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• Sequencing of irradiation and chemotherapy for early-stage breast cancer.

  1994cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• The development of biological therapies for breast cancer

  1993cited by this paper
• High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

  1993cited by this paper
• Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Risk of leukemia after chemotherapy and radiation treatment for breast cancer.

  1992cited by this paper
• Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute.

  1992cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

  1989cited by this paper
• Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

  1989cited by this paper
• Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients.

  1989cited by this paper
• Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.

  1989cited by this paper
• Ovarian function and adjuvant chemotherapy for early breast cancer.

  1987cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Complete axillary lymph node dissection for stage I-II carcinoma of the breast.

  1986cited by this paper
• Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

  1986cited by this paper
• Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients.

  1986cited by this paper
• Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.

  1985cited by this paper
• Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

  1984cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper
• Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture.

  1980cited by this paper
• Preliminary report from the Scandinavian adjuvant chemotherapy study group.

  1971cited by this paper
• Status of adjuvant therapy. Results of the national surgical adjuvant breast project studies on oophorectomy, postoperative radiation therapy, and chemotherapy. Other comments concerning clinical trials

  1971cited by this paper
• INFECTION IN INFANCY.

  1965cited by this paper
• Conservative Treatment of Cancer of the Breast*

  1937cited by this paper
• Artificial Menopause in Carcinoma of the Breast

  1934cited by this paper
• On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

  1896cited by this paper
• I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894.

  1894cited by this paper

• Pathological characteristics predicting sentinel lymph node metastasis in early breast cancer patients

  2024cites this paper
• In Silico Structure Activity Relationship Analysis on a Set Of ERΑ Inhibitors

  2019cites this paper
• HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

  2016cites this paper
• An overview of, Biomarkers in Carcinoma breast and, the relevance of ER/PR and HER-2/neu markers

  2014cites this paper
• Transcriptomic and Metabolomic Differentiation of Breast Cancers: Progression and Therapy Response via Magnetic Resonance Spectroscopy and Quantitative Expression Profiling in the Choline pathway

  2014cites this paper
• Predictors of Sentinel Node Involvement

  2014cites this paper
• Predictors of Sentinel Node Involvement in Breast Cancer

  2014cites this paper
• Mechanical phenotyping of breast cancer using MEMS: a method to demarcate benign and cancerous breast tissues.

  2014cites this paper
• Nanocomposite particles as theranostic agents for cancer

  2012cites this paper
• Identification and Validation of Candidate Breast Cancer Biomarkers: A Mass Spectrometric Approach

  2012cites this paper
• Linfadenectomía axilar en el cáncer de mama y melanoma

  2009cites this paper
• Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway

  2009cites this paper
• Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate

  2008cites this paper
• Rol de la linfadenectomía en el manejo quirúrgico del cáncer de mama

  2008cites this paper
• Gene Expression Profiling of Breast Cancer to Select Women for Adjuvant Chemotherapy

  2008cites this paper
• Short- and long-term cause-specific survival of patients with inflammatory breast cancer

  2005cites this paper
• Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.

  2005cites this paper
• Prognostic factors for breast cancer and their use in the clinical setting

  2005cites this paper
• The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer.

  2005cites this paper
• When Not to Treat – Chemotherapy for Small (≤ 1 cm) Breast Cancers

  2004cites this paper
• Laparoscopic oophorectomy combined with breast surgery for breast cancer patients

  2004cites this paper
• Selecting adjuvant endocrine therapy for breast cancer.

  2004cites this paper
• The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer

  2004cites this paper
• Lymphedema after treatment of breast cancer.

  2004cites this paper
• Development of Malignant Breast Microcalcifications After Neoadjuvant Chemotherapy in Advanced Breast Cancer

  2004cites this paper
• Choline metabolites as diagnostic and therapeutic response indicators for breast cancer

  2004cites this paper
• Molecular prognostic factors for breast cancer metastasis and survival.

  2002cites this paper
• Breast carcinoma treatment received by women with disabilities compared with women without disabilities

  2002cites this paper
• IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content.

  2002cites this paper
• Biochemical markers in breast cancer: which ones are clinically useful?

  2001cites this paper
• Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast

  2001cites this paper
• Adjuvant Treatment in Node-Negative, Postmenopausal Breast Cancer

  2001cites this paper
• Use of paclitaxel in patients with pre‐existing cardiomyopathy: A review of our experience

  2001cites this paper
• Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.

  2001cites this paper
• Serum and Tissue Markers for Breast Cancer

  2001cites this paper
• High-dose mitoxantrone adjuvant chemotherapy does not prolong survival for women with breast cancer and ten or more involved axillary nodes

  2001cites this paper
• Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

  2001cites this paper
• Chemotherapy of Metastatic Breast Cancer TAXANES : DRUGS OF THE 1990 S The introduction of paclitaxel ( Taxol ®

  2001cites this paper
• Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

  2000cites this paper
• Status of aromatase inhibitors in relation to other breast cancer treatment modalities.

  1999cites this paper
• Breast cancer treatment and chemoprevention.

  1999cites this paper
• Ensuring Quality Cancer Care

  1999cites this paper
• Thrombophilic State in Breast Cancer

  1999cites this paper
• ASSESSMENT OF THE QUALITY OF CANCER CARE: A REVIEW FOR THE NATIONAL CANCER POLICY BOARD OF THE INSTITUTE OF MEDICINE

  1998cites this paper
• Complications of axillary lymph node dissection for carcinoma of the breast

  1998cites this paper
• Clinical practice guidelines for the care and treatment of breast cancer: 7. Adjuvant systemic therapy for women with node-negative breast cancer (2001 update)

  year unknowncites this paper
• Clinical practice guidelines for the care and treatment of breast cancer : 8 . Adjuvant systemic therapy for women with node-positive breast cancer ( 2001 update )

  year unknowncites this paper